Market news — every asset we track

Assets

AEON

12 Health Care Stocks Moving In Thursday's After-Market Session

Sep 10Benzinga

AEON

12 Health Care Stocks Moving In Thursday's Intraday Session

Sep 10Benzinga

TNON

AEON

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Sep 10Benzinga

TNON

AEON

12 Health Care Stocks Moving In Wednesday's After-Market Session

Sep 9Benzinga

EXOZ

AEON

Laidlaw initiates Aeon Biopharma stock coverage with buy rating

Sep 9Investing.com

AEON

AEON Biopharma names Paul Lee as acting chief regulatory officer

Aug 24Investing.com

AEON

AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer

- Former Deputy Director of the FDA’s Office of Neuroscience - Dr. Lee has previously advised AEON through Clintrex Research LLC (Clintrex), an affiliate...

Aug 24Barchart.com

AEON

Aeon Biopharma director Timothy Lynch buys $243,455 in stock

Aug 22Investing.com

AEON

H.C. Wainwright cuts Aeon Biopharma stock price target on dilution

Aug 17Investing.com

AEON

Analysts Offer Insights on Healthcare Companies: AEON Biopharma (AEON) and Immix Biopharma (IMMX)

Detailed price information for Aeon Biopharma Inc (AEON-A) from The Globe and Mail including charting and trades.

Aug 15The Globe and Mail

IMMX

AEON

AEON Biopharma Reports Q2 Results, Advances ABP-450 Program

Detailed price information for Aeon Biopharma Inc (AEON-A) from The Globe and Mail including charting and trades.

Aug 13The Globe and Mail

AEON

AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

- Executed a $15.3 million financing with milestone warrants providing potential for an additional $34.0 million in gross proceeds, supporting continued advancement of ABP-450's development program

Aug 12Barchart.com

AEON

AEON Biopharma Regains NYSE American Listing Compliance

Detailed price information for Aeon Biopharma Inc (AEON-A) from The Globe and Mail including charting and trades.

Aug 4The Globe and Mail

AEON

AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards

ALISO VIEJO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company...

Aug 3Barchart.com

AEON

AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding

Detailed price information for Aeon Biopharma Inc (AEON-A) from The Globe and Mail including charting and trades.

Jul 14The Globe and Mail

AEON

This is the newest page. Registered accounts read further back.